Baillie Gifford & CO Acadia Pharmaceuticals Inc Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding ACAD
# of Institutions
280Shares Held
156MCall Options Held
901KPut Options Held
314K-
Baker Bros. Advisors LP New York, NY42.9MShares$698 Million7.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.8MShares$225 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$223 Million3.36% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$196 Million0.0% of portfolio
-
State Street Corp Boston, MA5.97MShares$97.2 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.63B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...